(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 November 2021 (11.11.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/224471 A1

(51) International Patent Classification:
A61K 31/454 (2006.01) *A61K 9/16* (2006.01)
A61K 31/573 (2006.01) *A61K 9/20* (2006.01)
A61K 31/58 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2021/062188

(22) International Filing Date:
07 May 2021 (07.05.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

20173749.1	08 May 2020 (08.05.2020)	EP
63/142,919	28 January 2021 (28.01.2021)	US
63/174,282	13 April 2021 (13.04.2021)	US

(71) Applicant: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: **QUINTEN, Thomas, Ronald, A**; c/o: Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). **DELAET, Urbain, Alfons, C**; c/o: Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). **HEYNS, Philip, Erna, H**; c/o: Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). **MARCOZZI, Tatiana**; c/o: Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). **BERTELS, Johny**; c/o: Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). **LUYTEN, Katrien**; c/o: Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). **TAMBWEKAR, Kaustubh, Ramesh**; c/o: Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). **LOPEZ-GITLITZ, Angela**; c/o: Janssen Research & Development, LLC 920 US Route 202 PO Box 300, Raritan, NJ 08869 (US). **HARTMAN KOK, Paul, J, A**; c/o: Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE).

(74) Agent: **CAMPABADAL MONFA, Gemma**; J&J Patent Law Department Turnhoutseweg 30, 2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

WO 2021/224471 A1

(54) Title: PHARMACEUTICAL FORMULATIONS OF ABIRATERONE ACETATE AND NIRAPARIB

(57) Abstract: The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.